Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22614733 | 0.98 | CES2 (0.47) | CES2CES1CYP2D6KMT2ACHRM2 | |
| SCHEMBL508009 | 0.84 | CES2 (0.52) | CES2CES1CYP2D6KMT2ACHRM2 | |
| SCHEMBL9559796 | 0.82 | ALDH1A1 (0.55) | CYP2D6CHRM2ADRA2BADRA2CCHRM3 | |
| SCHEMBL21753375 | 0.82 | SLC6A2 (0.46) | CYP2D6KMT2ACHRM2ADRA2BADRA2C | |
| SCHEMBL16868406 | 0.82 | ALDH1A1 (0.55) | CYP2D6CHRM2ADRA2BADRA2CCHRM3 | |
| SCHEMBL1707132 | 0.81 | CYP2D6 (0.36) | CYP2D6KMT2ACHRM2ADRA2BADRA2C | |
| SCHEMBL28312772 | 0.81 | CA1 (0.52) | CYP2D6KMT2ACHRM2ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL22614731 | 0.79 | CYP2D6 (0.36) | CYP2D6KMT2ACHRM2ADRA2BADRA2C | |
| SCHEMBL1230893 | 0.79 | SLC7A5 (0.42) | CES2CES1KMT2AANPEPENPEP | |
| SCHEMBL11043243 | 0.78 | CES2 (0.46) | CES2CES1CYP2D6KMT2ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444283-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | claimed |
| CN-110554018-A | Surface enhanced Raman material for detecting 4-bromomethcathinone in aqueous solution and preparation method thereof | SHANGHAI CRIMINAL SCIENCE TECH RESEARCH INSTITUTE | 2019-12-10 | — | — | CN | claimed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| EP-3841085-B1 | NBOME TEST | UNIV SYDNEY TECHNOLOGY (AU) | 2026-05-06 | — | — | EP | disclosed |
| EP-4687880-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | Tactogen Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260027148-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260021069-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260014191-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260014190-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12472201-B2 | Complexing agent salt formulations of pharmaceutical compounds | BEXSON BIOMEDICAL, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-11534454-B2 | Complexing agent salt formulations of pharmaceutical compounds | BEXSON BIOMEDICAL, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2022109050-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220152088-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. | 2022-05-19 | — | — | US | disclosed |
| CN-110554018-A | Surface enhanced Raman material for detecting 4-bromomethcathinone in aqueous solution and preparation method thereof | SHANGHAI CRIMINAL SCIENCE TECH RESEARCH INSTITUTE | 2019-12-10 | — | — | CN | disclosed |
| CN-110554018-A | Surface enhanced Raman material for detecting 4-bromomethcathinone in aqueous solution and preparation method thereof | SHANGHAI CRIMINAL SCIENCE TECH RESEARCH INSTITUTE | 2019-12-10 | — | — | CN | disclosed |
| CN-110554018-A | Surface enhanced Raman material for detecting 4-bromomethcathinone in aqueous solution and preparation method thereof | SHANGHAI CRIMINAL SCIENCE TECH RESEARCH INSTITUTE | 2019-12-10 | — | — | CN | disclosed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014191-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC6A4, SLC6A3, SIGMAR1 | CES2 366/4885CES1 2735/4885CYP2D6 25/4885 |
| US-20260021069-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | HCN1, HCN4, CRH | CES2 140/4885CES1 714/4885CYP2D6 677/4885 |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | MC1R, TYR, MITF | CES2 2861/4885CES1 3093/4885CYP2D6 385/4885 |
| US-20260027148-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC6A3, SIGMAR1, SLC6A4 | CES2 436/4885CES1 2747/4885CYP2D6 29/4885 |
| US-20220152088-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC10A1, SLC5A6, MC2R | CES2 2013/4885CES1 2938/4885CYP2D6 1358/4885 |
| US-11534454-B2 | Complexing agent salt formulations of pharmaceutical compounds | SLC10A1, SLC5A6, MC2R | CES2 2013/4885CES1 2938/4885CYP2D6 1358/4885 |
| US-12472201-B2 | Complexing agent salt formulations of pharmaceutical compounds | SLC10A1, SLC5A6, MC2R | CES2 2013/4885CES1 2938/4885CYP2D6 1358/4885 |
| US-20260014190-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SIGMAR1, OPRK1, SLC6A2 | CES2 545/4885CES1 2465/4885CYP2D6 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.